Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
Kyverna Therapeutics Q3 EPS $(0.68) Beats $(0.69) Estimate
Kyverna Therapeutics Completes BLA Submission For Miv-Cel In SPS Completed With Request For Priority Review; Says KYSA-6 Phase 3 gMG Trial Enrollment On-Track For Completion In Mid-2027
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
Kyverna Therapeutics Publishes Primary Analysis Of KYSA-8 Trial In Participants With Stiff Person Syndrome In Journal Of American Medical Association Neurology
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Kyverna Therapeutics: Fascinating CAR-T Science, Tricky Commercial Outlook
Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Kyverna Therapeutics To Present Full One-Year Data Set From KYSA-8, Registrational Trial Of Miv-Cel In Patients With Stiff Person Syndrome, At MS Toronto 2026, Joint ACTRIMS-ECTRIMS Meeting
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow
Kyverna stock jumps on positive one-year therapy data
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.